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Abstract
Despite substantial advances in treatment and management strategies for major depression,
less than 50% of patients respond to first-line antidepressant treatment or psychotherapy.
Given the growing number of controlled studies of psychotherapy for treatment-resistant
depression (TRD) and the preference for psychotherapy of depressed subjects as a treatment
option, we conducted a meta-analysis and meta-regression analysis to investigate the effective-
ness of psychotherapy for TRD. Seven different psychotherapies were studied in 21 trials that
included a total of 25 comparisons. In three comparisons of psychotherapy v. treatment as
usual (TAU) we found no evidence to conclude that there is a significant benefit of psycho-
therapy as compared with TAU. In 22 comparisons of add-on psychotherapy plus TAU v.
TAU only, we found a moderate general effect size of 0.42 (95% CI 0.29–0.54) in favor of psy-
chotherapy plus TAU. The meta-regression provided evidence for a positive association
between baseline severity as well as group v. individual therapy format with the treatment
effect. There was no evidence for publication bias. Most frequent investigated treatments
were cognitive behavior therapy, interpersonal psychotherapy, mindfulness-based cognitive
therapy, and cognitive behavioral analysis system of psychotherapy. Our meta-analysis pro-
vides evidence that, in addition to pharmacological and neurostimulatory treatments, the
inclusion of add-on of psychotherapy to TAU in guidelines for the treatment of TRD is jus-
tified and will provide better outcomes for this difficult-to-treat population.
Introduction
Major depressive disorder (MDD) is a highly prevalent and disabling psychiatric condition.
Despite substantial advances in treatment and management strategies for MDD, less than
50% of patients respond to first-line antidepressant treatment or psychotherapy (Cuijpers
et al., 2013; Kolovos et al., 2016). MDD that is treatment refractory, mostly described as
treatment-resistant depression (TRD), is characterized by marked functional impairment, a
large burden on patients and families, and is associated with great direct and indirect health-
care costs (Greden, 2001; Moussavi et al., 2007).
Clinical reviews suggest a prevailing inclination to manage TRD (solely) by pharmacother-
apy or other somatic treatments while scarcely mentioning studies into psychotherapy for
TRD with little or no discussion of the findings and prospects (e.g. Carvalho et al., 2014;
Dold and Kasper, 2016). This may be imprudent because (i) the likelihood of remission is con-
siderably reduced for individuals who require third or fourth-line antidepressant treatment
due to non-response in prior steps (Rush et al., 2006), (ii) a majority of depressed individuals
seems to prefer psychotherapy over medication (McHugh et al., 2013), and (iii) patients receiv-
ing their preferred treatment show better outcomes (Gelhorn et al., 2011; Mergl et al., 2011;
Swift et al., 2011; McHugh et al., 2013). Given these considerations, there is a need to thor-
oughly evaluate psychotherapy as a treatment option for TRD and accordingly formulate
recommendations for clinical practice.
High-quality studies that specifically sought to examine the effectiveness of psychothera-
peutic treatments for TRD are scarce and virtually absent until the beginning of this millen-
nium. In 2002, Stimpson, Agrawal, and Lewis conducted a systematic review of randomized
controlled trials (RCTs) for TRD but no psychotherapy studies met their minimal inclusion
criteria at that point. Two more recent reviews, based on seven RCTs and eight uncontrolled
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studies, concluded that psychotherapy either as augmentation or
substitute therapy could be an effective and reasonable treatment
for TRD (McPherson et al., 2005; Trivedi et al., 2011). The
authors emphasized the need for more high-quality, controlled
trials to effectively judge the utility of psychotherapy for TRD
and guide clinical practice.
Moreover, there is considerable variation in and confusion
about definitions of TRD and chronic depression (cMDD) in
the literature (Ruhe et al., 2012). As a result, many studies into
the psychotherapeutic treatment of cMDD appear to be carried
out in clinical samples that in the majority consist of participants
that already received one or more failed treatments for the index
episode, thereby qualifying them, in fact, as studies of psychother-
apy for TRD.
Given the considerations above and a growing database of ran-
domized controlled studies treating TRD with psychotherapy, we
decided to conduct a meta-analysis and meta-regression. For
these analyses, we collected all randomized controlled studies of
psychotherapy for adult patients with TRD and/or unsuccessfully
treated cMDD in which the effectiveness of psychotherapy was
examined as either a substitute for or add-on to treatment as
usual (TAU; routine treatments such as clinical management
and/or the continuation, optimization or next step pharmacother-
apy). We hypothesized (i) that switching to psychotherapy is
more effective than TAU, and (ii) psychotherapy as an add-on
to TAU to be more effective than TAU only.
Methods
Search strategy and study selection
Two authors (SB and NM) independently performed a compre-
hensive search through PubMed, Embase and PsychINFO elec-
tronic databases combining terms regarding psychotherapy, and
TRD/cMDD (online Supplementary Methods I). Publications
up until and including 19 December 2016 were reviewed. The
search was limited to articles published in English, describing
studies with a controlled design in samples of adult participants.
References of the selected articles were checked, as well as refer-
ences of earlier systematic reviews and meta-analyses
(McPherson et al., 2005; Cuijpers et al., 2010c; Trivedi et al.,
2011; Spijker et al., 2013; Kriston et al., 2014; Negt et al., 2016).
The same authors independently assessed articles for inclusion
by screening titles and abstracts followed by detailed full-text
evaluation if necessary. Disagreements between the reviewers
were solved through discussion with a third independent reviewer
(FP). We included (i) RCTs that examined the effectiveness of
psychotherapy for (ii) adults (⩾18 years of age) with TRD by
comparing (iii) psychotherapy v. TAU or (iv) add-on psychother-
apy and TAU v. TAU only. For this meta-analysis, we defined
TRD in line with previous reviews (Stimpson et al., 2002;
McPherson et al., 2005; Trivedi et al., 2011), as an individual’s
failure to respond to at least one adequate trial of antidepressants
for the current episode irrespective of duration of the current epi-
sode. We decided to apply this broad definition to enable compar-
isons with previous literature and to include a large body of
evidence. A failed response was assumed when study sample
descriptions mentioned the inclusion of participants not meeting
the criteria for clinically significant response or remission to the
previous treatment. For the current meta-analyses, we included
cMDD studies if the majority of the sample fulfilled our criterion
for TRD. Psychotherapy was defined as a face-to-face interaction
with a therapist, which was allowed to be delivered either in a
group or individual format in both out- and inpatient settings.
TAU was defined as treatments that individuals would normally
receive in routine (mental) health care, such as clinical manage-
ment and pharmacotherapy. Pharmacotherapy included continu-
ation, optimization, switching or starting of antidepressant
medication. Studies were excluded if they had a maintenance
treatment study design or if treatment-resistance was undefined
or remained unclear based on the reported information on previ-
ously failed response to antidepressant medication.
Quality assessment and data extraction
Two authors (SB and FP) independently evaluated the validity of
the studies eligible for the qualitative synthesis. Following recent
meta-analyses (Cuijpers et al., 2014, 2015), we examined all
included studies on four criteria of the ‘Risk of bias’ assessment
tool, developed by the Cochrane Collaboration (Higgins and
Green, 2011): (1) adequate random sequence generation, (2) allo-
cation to treatments by an independent (third) party, (3) blinding
of the outcome assessment and (4) the quantity, nature and man-
agement of incomplete outcome data. Disagreements between the
reviewers were resolved through discussion.
Two authors (NM and LB) independently extracted the data
from the included studies. Data extraction was checked and dis-
agreements were resolved by two other reviewers (FP and SB).
For the outcome variable, means and standard deviations (S.D.)
of change in depression severity scales from pre- to post-
intervention were extracted for both the treatment and TAU con-
dition. Our research questions addressed outcomes of acute-phase
treatment specifically. Therefore, the post-treatment endpoint was
set a maximum of 16 weeks with a minimum session frequency of
once a week. Follow-up measurements were excluded from our
analyses. Although the treatment endpoint was set at 16 weeks
to target the acute phase, for some studies outcome data were
not available at this time point. As a result, the post-intervention
depression severity score was assessed at 12.8 weeks on average,
varying between 5 and 26 weeks. In addition, we extracted clinical
variables, treatment variables and study variables for background
information input for sensitivity analyses, and meta-regressions
(as described in the ‘Statistical Analyses’ section). Clinical vari-
ables included the male/female ratio, the mean age of the sample,
mean depression severity at baseline, prior history (number of
previous episodes and mean illness duration in months), mean
duration of the current episode and the percentage of participants
that did not respond to antidepressants or psychotherapy for the
current episode prior to the study. Treatment variables included
the type of psychotherapy, treatment duration (number of months
and number of treatment sessions), individual or group setting,
attrition rates, and treatment integrity. Study variables included
the year the study was conducted, the clinical setting (inpatient
or outpatient), and an intention to treat approach for the
extracted outcome measures.
For each study, we coded the type of comparison: (1) psycho-
therapy v. TAU or (2) add-on psychotherapy plus TAU v. TAU.
In addition, we specified the type of interventions that were con-
sidered TAU. For a few studies comparing the ‘add-on psycho-
therapy plus TAU v. TAU’, the TAU interventions were slightly
different between the two groups. If so, this was coded during
our data extraction.
All corresponding authors were contacted to check the data
retrieved during our data extraction and were asked to provide
Psychological Medicine 367
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missing data. If those attempts failed and the incomplete data
made the calculation of an effect size impossible, studies were
excluded from the quantitative but not the qualitative synthesis
of evidence.
Statistical analyses
All analyses were done with Stata version 13.1. The primary out-
come was the difference between the average depression severity
change of treatment and control condition, calculated as
Hedges’ g effect sizes. If multiple instruments were available to
assess symptomatic change, the mean effect size was calculated
(Borenstein et al., 2009). To test whether studies with multiple
depression severity scales affected the overall results of the
meta-analyses, sensitivity analyses were performed with only
studies using one measurement scale. Since most studies had a
small sample size, effects sizes were corrected for small sample
bias (Hedges’ g). If average change scores were not reported,
they were calculated using the average pre and post-intervention
depression severity score. When unavailable, S.D. of the change
scores were calculated using the S.D. of the average pre- and post-
intervention depression scores and the correlation coefficient
between these scores (calculations were based on the formula pre-
sented in online Supplementary Methods II). If this correlation
coefficient was not reported, we assumed a correlation of r =
0.5, which was based on data from a recent RCT comparing cog-
nitive therapy and interpersonal psychotherapy for MDD
(Lemmens et al., 2015). To examine the impact of this assump-
tion, a sensitivity analyses were performed to test whether a
reduced (r = 0.2) or increased (r = 0.8) correlation would change
the overall results of the meta-analysis.
Summary effect sizes were pooled using a random-effects
model for (i) psychotherapy v. TAU or (ii) add-on psychotherapy
plus TAU v. TAU comparison. To test the homogeneity of the
effect sizes, the I2 statistic was estimated with 95% confidence
intervals (Ioannidis et al., 2007). An I2 value of >50% was
assumed to be indicative of heterogeneity. When multiple com-
parisons of one trial were included, sensitivity analyses were per-
formed to test whether this affected the pooled results by only
including the comparison with the smallest effect size. In add-
ition, sensitivity analyses on study quality were conducted by lim-
iting the analyses to the studies meeting all four quality criteria
with a low-risk score. For the second comparison, studies with
slightly different TAU interventions between the two groups
were excluded to see whether this affected the pooled effect size
(additional sensitivity analysis). A similar sensitivity analysis
was computed for studies with the inclusion of psychotherapy
in the TAU interventions. We assessed publication bias by
inspecting funnel plots and examining plot asymmetry using
the Egger’s test (Egger et al., 1997).
A meta-regression was conducted in order to relate specific
study-level variables to the statistical heterogeneity between the
results of the studies (Thompson and Higgins, 2002). First, we
conducted univariate meta-regressions for each of the following
a priori selected variables: mean depression severity at baseline,
mean illness duration (number of months and number of previous
episodes), mean duration of the current episode, the percentage of
participants that did not respond to antidepressants for the cur-
rent episode, mean treatment duration (number of months and
number of treatment sessions), attrition rates, the clinical setting
(inpatient or outpatient), individual or group format, clinician-
rated or self-reported outcomes (or a combination), and whether
the extracted outcomes were based on intention to treat data.
When variables had at least a p value <0.10, they were included
in a multivariate meta-regression. Correlations between the vari-
ables that were included in the multivariate meta-regression
were examined to check if collinearity could influence the results.
Results
Selection and inclusion of trials
We identified 1044 potentially relevant citations through database
searching and 16 additional records through other sources. After
removing duplicates and excluding non-relevant citations based
on abstract examination, we retrieved 32 full-text papers for fur-
ther consideration. Finally, 22 trials met our inclusion criteria
for the meta-analysis, however, 1 trial was only included in the
qualitative analysis as a result of reporting incomplete data. The
PRISMA flow chart describing the inclusion process and exclu-
sion reasons is presented in Fig. 1.
Characteristics of included trials
The 21 trials included in the meta-analyses provided a total of 25
comparisons; three comparisons (three studies) pertained to psy-
chotherapy v. TAU (Table 1), and 22 (20 studies) to a comparison
of add-on psychotherapy plus TAU v. TAU only (Table 2). A total
of 3539 patients were enrolled (293 in psychotherapy only, 1588
in add-on psychotherapy plus TAU and 1638 in TAU). Sample
sizes varied between 11 and 235 participants per treatment arm.
All trials (22 with the inclusion of the one study that was
retained in the qualitative analysis only) recruited participants
in secondary or tertiary care facilities except for one that was con-
ducted in primary care (Wiles et al., 2013). Two trials were con-
ducted in an inpatient setting. Eight trials were conducted in
North- and South America, nine in the UK, four in other
European countries, and one in East Asia.
In total, 11 different psychotherapeutic treatments were inves-
tigated. In the 25 comparisons, six examined cognitive behavior
therapy (CBT), six cognitive behavioral-analysis system of psy-
chotherapy (CBASP), two interpersonal psychotherapy (IPT),
four mindfulness-based cognitive therapy (MBCT). The number
of treatment sessions varied from 8 to 60 (although treatment
endpoint for further analyses was set at 16 weeks to target the
acute phase which restricted the range between treatments, see
method section). Fourteen comparisons used an individual for-
mat, 10 employed a group format, and one utilized a mixed indi-
vidual and group approach.
In the psychotherapy v. TAU comparison, TAU conditions
included starting of (Keller et al., 2000; Schramm et al., 2015)
and switching to (Thase et al., 2007) different types of antidepres-
sant medication. TAU interventions in the add-on psychotherapy
plus TAU v. TAU comparison included clinical management,
and starting, augmenting, optimizing, and continuing pharmaco-
therapy. Changes in antidepressant medication (starting, augment-
ing and optimizing) were guided by a study protocol (Barker et al.,
1987; Keller et al., 2000; Kennedy et al., 2003; Schramm et al., 2007;
Thase et al., 2007; Kocsis et al., 2009) or left to the decision of clin-
icians (Murray et al., 2010; Wiles et al., 2013; Wiersma et al., 2014;
Fonagy et al., 2015; Michalak et al., 2015; Eisendrath et al., 2016;
Souza et al., 2016). For a few studies comparing add-on psychother-
apy plus TAU v. TAU, TAU conditions involved psychotherapy
options (not for all participants) (Murray et al., 2010; Watkins
368 Suzanne van Bronswijk et al.
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et al., 2011; Wiles et al., 2013; Wiersma et al., 2014; Fonagy et al.,
2015; Michalak et al., 2015), psycho-education (Chiesa et al., 2015),
a health enhancement program (Eisendrath et al., 2016) or other
health care services (Harley et al., 2008; Barnhofer et al., 2009;
Wiersma et al., 2014). In nine of 22 ‘psychotherapy plus TAU v.
TAU’ comparisons, the TAU interventions were slightly differ-
ent between the two groups (Kennedy et al., 2003; Schramm
et al., 2007; Thase et al., 2007; Murray et al., 2010; Watkins
et al., 2011; Wiersma et al., 2014; Chiesa et al., 2015; Fonagy
et al., 2015; Eisendrath et al., 2016).
Studies used various instruments to examine depression severity,
including clinician-rated measures (Hamilton Rating Scale for
Depression Scale, Montgomery-Asberg Depression Rating Scale,
Quick Inventory of Depressive Symptomatology) and self-report mea-
sures (Inventory of Depressive Symptomatology, Beck Depression
Inventory, Quick Inventory of Depressive Symptomatology).
Quality of included trials
Thirteen of the 22 studies met all four quality criteria with a ‘low
risk’ score. A total of 18 studies reported an adequate random
sequence generation. In 19 studies, it was reported that the
treatment allocation was done by an independent party. In 23
studies, the outcome assessors were blinded to the treatment allo-
cation. A total of 15 studies used intention-to-treat analyses and
had a balanced number of missing outcome data across
interventions.
Treatment integrity
Two of the 22 studies did not report information on the thera-
pist’s competence in and adherence to the specific treatment
type (Barker et al., 1987; Kennedy et al., 2003). Of the remaining
20 studies, seven trials provided extra training for the therapists
prior to the study. Therapists received supervision (individual
and/or group) in 17 studies, and sessions were video or audio
recorded in 13 studies. Adherence was systematically rated in
eight studies, of which two used ‘checklists’ and the remaining
six used standardized instruments. Competence was systematic-
ally assessed in five studies with standardized instruments.
Detailed information about treatment integrity for each study is
provided in online Supplementary Results I.
Fig. 1. Study selection process.
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TRD, treatment-resistant depression; TAU, treatment as usual; ADM, antidepressant medication; PT, psychotherapy; CBASP, Cognitive Behavioral Analysis System of Psychotherapy; NFN, Nefazodon; CM, clinical management; HAM-D24, 24-item Hamilton
Rating Scale for Depression; CTM, Citalopram; CBT, cognitive behavioral therapy; BUP, bupropion; SER, sertraline; VLX, venlafaxine; HAM-D17, 17-item Hamilton Rating Scale for Depression; QIDS-C, clinician-administered version of the 16-item Quick
Inventory of Depressive Symptomatology; ECM, Escitalopram; MADRS, Montgomery-Asberg Depression Rating Scale; IDS-SR, self-report version of the Inventory of Depressive Symptomatology.
aStudy quality was examined using four criteria of the ‘‘Risk of bias’’ assessment tool, developed by the Cochrane Collaboration (Collaboration 2015). A positive (low risk) or negative sign (high risk or unclear) is given to each of the criteria respectively:
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We examined three studies consisting of three comparisons (see
Table 1). Interventions were CBT and CBASP. The TAUs as
described in the trials were mainly a continuation of ongoing
pharmacotherapy.
The mean pooled effect size was g =−0.13 (95% CI −0.30 to
0.05), heterogeneity was low with a high level of uncertainty
given the wide 95% CI interval (I2 = 0.00: 95% CI 0.00–89.60).
The effect sizes of the individual trials are plotted in Fig. 2, show-
ing that none of the interventions had significantly higher depres-
sion severity change scores on average than TAU. Given the small
number of studies, we did not perform an Egger’s test (Higgins
and Green, 2011). Separate sensitivity analyses (1) examining dif-
ferent correlations between pre- and post-intervention depression
scores, (2) excluding studies that used multiple outcome mea-
sures, (3) including only the comparison with the smallest effect
size, did not change the results, and (4) including only studies
meeting all four quality criteria with a low risk score. Given the
small number of included studies, we were not able to conduct
a meta-regression.
Add-on psychotherapy plus TAU v. TAU
We examined 20 studies consisting of 22 comparisons for the
effectiveness of psychotherapy added to TAU v. TAU alone.
The psychotherapeutic interventions were IPT, CBASP, CBT,
psychodynamic therapy (PDT), body-oriented therapy (BOT),
dialectic behavior therapy (DBT) and brief supportive psycho-
therapy (BSP). The TAUs as described in the trials were mainly
a continuation of ongoing pharmacotherapy. Study characteristics
are shown in Table 2.
The mean pooled effect size was g = 0.42 (95% CI 0.29–0.54),
indicating that adding psychotherapy to TAU resulted in higher
average depression severity change as compared with treatment
with TAU alone (Fig. 3). We found an indication for heterogen-
eity between studies, with again large uncertainty around this esti-
mate (I2 = 52.96; 95% CI 23.6–71.04). When grouped together by
type of treatment, IPT (g = 0.33; 95% CI 0.02–0.64), CBASP (g =
0.42; 95% CI 0.08–0.76), CBT (g = 0.26; 95% CI 0.01–0.51), and
MBCT (g = 0.55; 95% CI 0.31–0.79) show moderate but signifi-
cant pooled effect sizes. Within the group of other therapies,
BOT, PDT, individual rumination-focused cognitive behavioral
therapy, and person-based cognitive therapy showed significant
effect sizes (Fig. 3). The funnel plot (Fig. 4) did not indicate pub-
lication bias and Egger’s test did not indicate asymmetry of the
funnel plot (intercept: 0.78; 95% CI −0.79 to 2.35; p = 0.31).
Separate sensitivity analyses (1) examining alternative correla-
tions between pre- and post-intervention depression scores, (2)
excluding studies that used multiple outcome measures, (3)
including only the comparison with the smallest effect size, (4)
excluding trials where the TAU in the control group was different
from the TAU in the intervention arm, (5) excluding trials where
TAU included psychotherapy options, and (6) including only
studies meeting all four quality criteria with a low-risk score,
did not change the results.
In the univariate meta-regression analyses regarding the set of
a priori selected variables, baseline severity (β = 0.16; S.E. = 0.09;
p = 0.079); divided into four categories between mild and very
severe (Rush et al., 2003), number of sessions (β =−0.12; S.E. =
0.06; p = 0.073), and individual v. group format (β = 0.32; S.E. =
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meta-regression higher baseline severity (β = 0.81; S.E. = 0.07;
p = 0.032), and group therapy-format (β = 0.38; S.E. = 0.20;
p = 0.079) were associated with a larger effect size. Their correl-
ation was 0.23, indicative of low collinearity.
Discussion
In the present meta-analysis, we investigated the effectiveness of
psychotherapy for adult patients with TRD and/or unsuccessfully
treated cMDD either as a substitute or as an add-on to TAU. We
identified 22 trials of which 21 could be included in the
meta-analyses, yielding a total of 25 comparisons. In three com-
parisons of psychotherapy v. TAU we found no significant advan-
tage of psychotherapy over TAU, while in 22 comparisons of
add-on psychotherapy plus TAU v. TAU only, we found a signifi-
cant improvement of patients due to psychotherapy with a mod-
erate general effect size of 0.42 (95% CI 0.29–0.55).
Psychotherapy v. TAU
Our hypothesis that for acute-phase treatment psychotherapy is
more effective than TAU in TRD was not confirmed. Compared
with ongoing TAU, psychotherapy, as a substitute for ongoing
or recently started TAU, psychotherapy appeared not more effect-
ive in TRD (Hedges’g =−0.02). We found no indication for pub-
lication bias and the heterogeneity between studies was small
although this should be interpreted with caution because CI inter-
vals were wide. In a previous meta-analysis (Cuijpers et al.,
2010c), addressing the effectiveness of psychotherapy for cMDD
and dysthymia, the authors reported that pharmacotherapy was
more effective than psychotherapy, which seems at odds with
our finding. However, it should be kept in mind that our inclusion
criteria (aimed at TRD and exclusion of dysthymia) resulted in a
selection of different studies. The vast majority of participants in
our study selection had not responded to at least one previous
trial with an antidepressant that is known to be associated with
a less favorable response to subsequent treatments with pharma-
cotherapy (Ruhe et al., 2006).
Add-on psychotherapy plus TAU v. TAU
We found that psychotherapy added to ongoing TAU has a mod-
erate and significant effect size (Hedges’g = 0.42) in comparison
with TAU alone in TRD. Again, there was no evidence for publi-
cation bias, however there was some indication of heterogeneity
between studies with wide CI intervals. The results from this
meta-analysis suggest that, in line with a previous meta-analysis
(Cuijpers et al., 2010c) and recent clinical recommendations
(Jobst et al., 2016) about the treatment of cMDD, several psycho-
therapeutic approaches may be of value in the treatment of TRD
when added to TAU, with some evidence for more effectiveness in
patients with more severe depressive symptomatology. However,
some considerations may apply. First, studies of the effectiveness
of CBT were done in samples with relatively low levels of TRD
(mostly one unsuccessful trial with an antidepressant), which
may restrict its applicability in patients with more advanced
TRD. Second, some studies (e.g. Keller et al., 2010) excluded par-
ticipants displaying high levels of TRD, like non-response to three
previous adequate trials of different classes of antidepressants or
electroconvulsive therapy, again limiting generalizability to
patients with more advanced levels of TRD. Third, based on
these findings one cannot rule out that TAU and psychotherapy
interfere and that the combination of the two interventions
leads to a greater impact than the sum of each treatment effect
separately. However, a recent meta-analysis on combination ther-
apy (pharmacotherapy and psychotherapy) for depression and
anxiety disorders has shown equal and independent effects of
pharmacotherapy and psychotherapy (Cuijpers et al., 2014).
Fig. 2. Effects of psychotherapy for TRD when substituted for TAU. g = Hedges’ g effect sizes, 95% CI = 95% confidence interval, DL = DerSimonian-Laird method:
between study variation was estimated using the DerSimonian-Laird method.
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Fourth, since no active and structural equivalent placebo condi-
tion was included, the current design is insufficient to examine
if the specific components of psychotherapy are responsible for
the moderate effect size (Baskin et al., 2003).
Meta-analyses of psychotherapy for non-TRD typically report
effect-sizes, that are comparable with the overall effect-size of g =
0.42 for psychotherapy as an add-on to TAU for TRD that we
have found (Cuijpers et al., 2008, 2010b). This is also commensur-
ate with the results from a meta-analysis that examined the effect-
iveness of psychotherapy for cMDD and dysthymia (Cuijpers
et al., 2010c).
In the current meta-analysis, the most frequently investigated
treatments are CBT, CBASP, MBCT, and to a lesser extent IPT,
all with small to moderate overall effect sizes. No significant dif-
ferences in the efficacy between the treatments emerged from the
meta-regression. This result should be interpreted with caution
since for each therapy a different number of comparisons was
included (ranging between one and five studies). In addition,
one could argue that aggregated results from RCTs are not suited
to isolate effects of specific psychotherapies (Budd and Hughes,
2009).
Clinical features and study characteristics
In our meta-regression we found no evidence, other than baseline
severity and group of individual treatment format, for an associ-
ation between variables such as mean duration of the current epi-
sode, mean treatment duration (number of months and number
of treatment sessions), attrition rates, clinician-rated or self-
reported outcomes, and an intention to treat approach for the
outcome measures. The lack of an association between effect
size and treatment duration or a number of sessions should be
interpreted with caution since we used results from acute-phase
treatment with an endpoint at approximately 16 weeks treatment
for sake of comparison and absence of long-term follow-up data
in many studies. Therefore, in the current study, we did not dem-
onstrate that more treatment sessions would result in significant
larger effect sizes like previously reported in a meta-analysis
examining the effectiveness of psychotherapy for cMDD and dys-
thymia (Cuijpers et al., 2010c). However, we found comparable
effects sizes between recent studies of MBCT and treatments of
longer duration, suggesting that the reported association between
a number of sessions and effect size may be not as strong as
Fig. 3. Effects of add-on psychotherapy plus TAU v. TAU for TRD. g = Hedges’ g effect sizes, 95% CI = 95% confidence interval, DL = DerSimonian-Laird method:
between study variation was estimated using the DerSimonian-Laird method, MBCT = Mindfulness Based Cognitive Therapy, CBASP = Cognitive Behavioral
Analysis System of Psychotherapy, BSP = Brief supportive psychotherapy.
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previously reported. It cannot be ruled out that some elements of
MBCT (e.g. daily application of exercises after treatment termin-
ation) have enduring effects beyond the typically 8 weeks duration
of training. In contrast to previous findings (Cuijpers et al.,
2010a), we did not find an effect of clinician-rated v. self-reported
instruments on our results. This result should also be interpreted
with caution since we used a combination of clinician-rated and
self-reported outcomes (average effect size) for 11 of the included
comparisons.
Studies that included participants with more baseline depres-
sion severity showed a larger effect-size. This is in line with pre-
vious findings that reported more efficacy of antidepressants in
more severely depressed subjects (Turner et al., 2008; Fournier
et al., 2010). An unexpected finding from the meta-regression
was the larger effect-size in studies that employed a group instead
of an individual treatment format. Several speculative explana-
tions can be put forward. First, group formats consist of longer
sessions than typical for individual treatment thereby increasing
therapy exposure, although the literature does not support this
speculation as there is no indication for greater efficacy of group
format compared with individual therapy (Huntley et al., 2012).
Additionally, one of the group therapies (MBCT) consists of
daily exercises outside of the strict session context thereby increas-
ing exposure to therapeutic interventions. Another explanation
may be that the group format also provides additional peer support
in subjects demoralized after unsuccessful previous treatment.
In the last decade, both the number and quality of psycho-
therapeutic trials in the field have increased considerably. The for-
mer is illustrated by the small number of studies that were
included in previous reviews and meta-analyses (Stimpson
et al., 2002; McPherson et al., 2005; Trivedi et al., 2011).
Quality improved because recent studies relied on solid random-
ization procedures, well-described treatments, and well-trained
therapists, used blinded outcome assessments, and reported
intention-to-treat instead of completers-only analyses. We con-
sider this a positive development given the preference for psycho-
therapy of many patients and the association between receiving a
preferred treatment and clinical outcome.
Generally, one of the problems in interpreting study results of
treatments for TRD is the lack of a uniform definition of TRD
which may range from non-response to only one treatment
trial, mostly with an antidepressant, to non-response following
intensive consecutive treatments including ECT (Ruhe et al.,
2012). Subsequently, non-response to only one treatment trial
might not be considered as a relevant level of TRD in clinical
practice. These different levels of treatment resistance impede
interpretation of the results from this meta-analysis and its applic-
ability in daily practice. A recommendation for future studies
would be to include detailed information on previous failed treat-
ments and include this in data-analysis. This can facilitate clinical
decision-making based on the level of treatment resistance.
Strengths and limitations
To our knowledge, this is the largest meta-analysis to date of stud-
ies into the effectiveness of psychotherapeutic treatments when
applied for the treatment of individuals with TRD. Although
studies specifically aimed at this clinically very important popula-
tion have been carried out in recent years, we were able to enlarge
the database by adding studies in cMMD that in fact included a
majority of patients with TRD. This enabled us to address the
clinically relevant question whether psychotherapy for TRD is
indeed effective. In addition, we extended this meta-analysis
with a meta-regression to relate specific study-level variables to
the statistical heterogeneity between the study results.
Some limitations apply to this meta-analysis. First, one of the
problems in interpreting study results of treatments for TRD is
the lack of a uniform definition of TRD which may range from
non-response to only one treatment trial (mostly with an anti-
depressant) to non-response following intensive consecutive treat-
ments including ECT (Ruhe et al., 2012). This is also illustrated by
the fact that the majority of the studies included participants that
were resistant to pharmacotherapy, no studies investigated specif-
ically the efficacy of psychotherapy after previous treatment with
some other form of psychotherapy. This impedes interpretation of
the results from this meta-analysis and its applicability in daily
practice. A recommendation for future studies would be to
include more detailed information on previous failed treatments
and include this in data-analysis and/or use validated tools to
quantify TRD (Peeters et al., 2016). Second, although effect-sizes
were roughly of equal magnitude, differences in content between
experimental interventions were large, which may limit guidance
for daily clinical practice; clinicians are confronted with many
remaining options. Third, the impact of treatment integrity and
therapists effects on the effectiveness of psychotherapy was not
evaluated, since standardized instruments to assess therapy adher-
ence and therapist’s competence were often lacking and informa-
tion of therapists effect was not included. Fourth, the number of
studies in the comparison between psychotherapy and TAU was
limited. Fifth, type and quality of the TAU conditions (mostly
pharmacotherapy and clinical management) were variable,
which may affect their validity as comparison intervention
resulting in an overestimation of effect sizes of the experimental
conditions. However, given their presumed reflection of common
clinical practice in these patients, this variability might improve
the generalizability of the results. Sixth, although we performed
meta-regression analyses to address the impact of potentially rele-
vant variables on outcome differences between studies, we did not
find significant results apart from baseline depression severity and
group/individual format. It should be noted that meta-regression
is an analysis of the influence at the level of differences between
and not within studies. Therefore, including variables at this
level, has its limitations because only sample means are used,
while ignoring the range in scores in the individual study popula-
tions (i.e. ecological bias; Thompson and Higgins, 2002). This
Fig. 4. Add-on psychotherapy plus TAU v. TAU for TRD: Funnel plot.
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limits adequate subgroup analyses and better examination of het-
erogeneity between subjects for which individual patient data
would be needed. Another limitation of our meta-regression is
the missing information on some variables, limiting the power
of our analyses. Eighth, we included studies of cMDD when a
majority of the participants were reported to have failed to
respond to at least one treatment trial for the current episode.
This might have resulted in the inclusion of some subjects who
were, in fact, true cMDD patients without qualifying for TRD,
which may have influenced the results. However, it should be
kept in mind that the majorities of non-responding patients in
the included studies were large. Additionally, we examined this
potential bias in the meta-regressions; the percentage of partici-
pants that did not respond to antidepressants for the current epi-
sode was not significantly associated with effect sizes. We,
therefore, feel that our results represent an accurate approxima-
tion of the effect size in TRD. Finally, as outlined earlier, we
were not able to pool long-term data from the few studies that
relied on treatments with longer duration and/or more treatment
sessions which may obscure additional beneficial results.
Conclusion
Our meta-analysis provides evidence that, in addition to pharma-
cological and neurostimulatory treatments, add-on of psychother-
apy to TAU in guidelines for the treatment of TRD is justified and
will provide better outcomes for this difficult-to-treat population.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S003329171800199X.
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